Jo Ann Horowitz, MD
Jo Ann Horowitz has more than 28 years of clinical drug development expertise in benign and malignant hematology and oncology, including design and implementation of Phase 1 through Phase IV clinical studies in patients with solid and hematological malignancies. She has worked on programs in patients with lung, colon, ovarian, melanoma and brain tumors as well as patients with aplastic anemia and iron overload. Jo Ann has also led cross functional drug development teams, resulting in regulatory approvals in these areas. During a successful pharmaceutical career at Lederle, Schering Plough, Merck and Novartis, Jo Ann has focused on transformative treatments with novel mechanisms of action including gene therapy (radp53, SCH58500) and immunotherapy (Keytruda) as well as cytokine development, targeted therapies, cytotoxic drug development (temozolomide approval for first line glioblastoma) and its bioequivalent formulation, thrombopoetin receptor agonist (eltrombopag approval for aplastic anemia) and iron chelation (jadenu for iron overload) . She has successfully imported external databases resulting in drug approvals and has met with regulatory agencies globally. She has participated in business development for sickle cell disease, and successfully participated in 3 mergers. Jo Ann is passionate about helping patients as she consults with pharma and biotech clients to develop and execute clinical development programs in areas of unmet medical need.